Astragalus: The Definitive Guide

What is astragalus?

Astragalus supplements usually use the dried root of Astragalus membranaceus, called huang qi or milk-vetch root. More than one species exists in the genus, so “astragalus” alone is not enough identity. Health Canada's 2025 monograph specifies A. membranaceus dry root for oral use. [1]

The root contains polysaccharides, saponins called astragalosides, flavonoids and other compounds. Extracts may emphasize different fractions. An astragaloside-IV marker, a polysaccharide percentage or an extract ratio describes a product; it does not prove that it matches a trial or produces a clinical effect.

“Adaptogen” and “immune support” are broad traditional or commercial categories. They do not establish prevention of infection, treatment of autoimmune disease or reversal of aging. [2]

Typical Astragalus Protocols

There is no RDA, AI or UL for astragalus. NCCIH notes that oral use up to 60 g/day for as long as four months has not appeared to cause major adverse effects, but also says a thorough safety evaluation has not been done. That observation is not a target dose or proof of long-term safety. [2]

Titration

The selected sources do not establish a general step-up schedule.

Timing

The kidney-trial abstract reports a daily raw-root equivalent but not enough detail to invent a meal or divided-dose schedule.

Duration

The selected oral trials lasted 28 days or 48 weeks in diagnosed populations. Neither duration establishes routine preventive use.

Stopping

No evidence-based taper is established. Stop and seek review for allergy, persistent digestive symptoms, worsening autoimmune symptoms, or clinically important glucose, blood-pressure or kidney changes.

What is astragalus commonly used for?

People use astragalus for fatigue, colds, “immune support,” kidney health, glucose control, allergies and longevity. NCCIH's current conclusion is that there is not enough reliable scientific evidence to know whether it is useful for any health condition. This reflects small studies, variable preparations, geographic concentration and high or unclear risk of bias. [2]

Recent reviews report signals when astragalus is added to metformin, kidney care or other treatment. A positive pooled biomarker does not show that an over-the-counter capsule prevents disease or replaces standard care. [2], [5], [6]

Which form and label details matter?

Read the label in this order:

1. Species: Astragalus membranaceus rather than the genus name alone.
2. Plant part: dried root.
3. Preparation: powder, decoction-equivalent, water or ethanol extract, or another fraction.
4. Amount basis: actual extract per serving and dried-root equivalent when provided.
5. Markers: astragaloside IV or polysaccharide statements describe composition but do not create dose equivalence.
6. Other ingredients: multi-herb formulas cannot establish astragalus's contribution.

Injectable PG2 polysaccharides used in oncology studies are a drug-like hospital preparation and are not equivalent to an oral root supplement. Results from injections should not be used to market capsules. [7]

What does the human evidence show?

Diabetic kidney disease

In the 2024 multicentre assessor-blinded trial, 118 adults with type 2 diabetes, stage 2–3 chronic kidney disease and macroalbuminuria were randomized to standard care alone or standard care plus oral astragalus granules equivalent to 15 g raw root daily for 48 weeks. The estimated eGFR decline was 4.6 mL/min/1.73 m² per year slower with astragalus. The UACR slope did not differ significantly. [3]

This is more informative than older uncontrolled claims, but it was not placebo-blinded and tested add-on care in a selected Hong Kong population. It does not support treating kidney disease independently, and the null UACR result must remain visible.

The 2014 Cochrane review found 22 studies with 1323 participants, overall low quality, inconsistent kidney-function findings and no reporting of its nominated primary outcomes of dialysis initiation or all-cause mortality. [6]

Type 2 diabetes

A 2024 review pooled 20 trials with 953 participants and reported lower fasting glucose and HbA1c when astragalus was added to treatment. The authors rated certainty and risk of bias as suboptimal. Different products and co-treatments prevent the pooled result from defining an oral supplement regimen. [5]

Post-stroke fatigue

A preliminary double-blind study assigned 64 people with post-stroke fatigue to 2.8 g three times daily or placebo for 28 days; 61 completed. It reported fatigue and quality-of-life changes, but one short, small study in stroke survivors does not establish treatment for general fatigue. [4]

Immune markers and infection claims

A 2023 review of 19 studies and 1094 participants reported changes in cytokines and immune-cell markers. NCCIH notes that the studies were small and heterogeneous. Changing an immune marker is not the same as preventing colds, improving vaccine response or making immunity “stronger.” [2], [8]

What remains uncertain

• whether an oral commercial product reproduces a studied preparation;
• clinically meaningful kidney outcomes such as dialysis or survival;
• prevention or treatment of respiratory infection;
• benefits for healthy people's fatigue, longevity or daily function;
• long-term safety, pregnancy and breastfeeding;
• clinically tested interactions with immunosuppressive and glucose-lowering medicines.

How might it work?

Polysaccharides, astragalosides and flavonoids have been studied for immune signaling, inflammation, endothelial function and glucose or kidney pathways. Much of this evidence is preclinical. Oral exposure and product composition vary, and an immune-marker change does not establish a health benefit.

Telomerase and telomere claims are especially easy to overstate. Laboratory activation or a small biomarker study does not show slower aging, longer life or cancer prevention. This guide does not treat a telomere result as a clinical outcome.

What are the risks and interactions?

NCCIH reports that oral astragalus may be tolerated, but a thorough safety evaluation is lacking. LiverTox describes gastrointestinal upset, diarrhea, nausea and vomiting at large doses and rates astragalus an unlikely cause of clinically apparent liver injury. Product purity and multi-ingredient attribution remain limitations. [2], [9]

People with autoimmune disease should avoid astragalus because it may worsen symptoms. Astragalus may oppose medicines that suppress the immune system. Health Canada requires professional advice for autoimmune disorders and pregnancy or breastfeeding. [1], [2]

Kidney, glucose and blood-pressure trials create monitoring questions, not permission to change prescribed care. Review astragalus with the clinician managing diabetes, kidney disease, transplantation, cancer or autoimmune treatment. Do not generalize injected oncology preparations to oral supplements.

Seek prompt care for severe allergy, fainting, severe vomiting or diarrhea, a marked autoimmune flare, possible low blood sugar, sudden swelling, reduced urine, shortness of breath or neurological symptoms.

Legal status in the United States and Canada

In the United States, oral astragalus products are sold as dietary supplements. FDA does not approve them for safety and effectiveness before sale, and they cannot legally claim to treat kidney disease, diabetes, infection, cancer or another disease. [2], [10]

In Canada, natural health products require a product licence and NPN. The 2025 monograph defines eligible A. membranaceus root materials, claims, daily equivalents and cautions. A licence does not prove effectiveness for kidney disease or infection. [1]

What should you monitor?

Record species, root preparation, extract ratio or marker, dried-root equivalent, lot, other ingredients and schedule. If kidney disease, diabetes, transplantation or immunosuppressive treatment is involved, use the clinical monitoring plan set by the treating team.

For fatigue, choose one repeatable measure and note sleep, infection, rehabilitation, mood and medicine changes. New fatigue after stroke or during cancer treatment needs assessment rather than a self-directed supplement trial.

What happens when you stop?

The selected evidence does not establish withdrawal, tapering or a required washout. Do not change immunosuppressive, diabetes, blood-pressure, kidney, stroke or cancer treatment because astragalus was started or stopped without the prescriber.

How should it be stored?

Follow the product label. Keep it closed, dry, away from heat and children, and discard damaged or expired products. Dried root, liquid extracts and capsules may have different storage instructions.

How does astragalus compare with other approaches?

Fatigue and recurrent illness can reflect sleep loss, anemia, medication effects, infection, mood, cardiopulmonary disease or endocrine problems. Kidney disease and diabetes require diagnosis, risk reduction and evidence-based treatment.

Ginseng, echinacea, reishi and medicinal mushroom products have different preparations, evidence and risks. No robust head-to-head evidence identifies a universally best adaptogen or immune supplement, and combining products makes attribution harder.

What do public communities add?

Public discussions raise questions about decoctions, root-equivalent amounts, telomeres, colds and energy. They cannot authenticate a species, measure eGFR change reliably, identify immune interactions or estimate adverse-event rates. Anecdotes do not set the dose or efficacy estimate here.

Common questions

Does astragalus boost immunity?

Some studies report immune-marker changes, but that does not prove fewer infections or universally better immunity. People with autoimmune disease should avoid it, and immunosuppressive medicines require review. [2], [8]

Does astragalus treat kidney disease?

No. One 48-week add-on trial found a slower eGFR decline but no significant UACR-slope difference. Older reviews found low-quality evidence and missing patient-important outcomes. [3], [6]

Can astragalus lower blood sugar?

A 2024 review reported glucose and HbA1c signals when astragalus was added to treatment, but study bias and product differences limit certainty. It must not replace diabetes care. [5]

Is 60 g per day a standard dose?

No. NCCIH's safety summary says use up to that amount has not appeared to cause adverse effects in limited data; it is not a target or a proven safe long-term regimen. [2]

Does astragalus lengthen telomeres or slow aging?

No clinical evidence shows that astragalus slows aging or extends life. Telomerase mechanisms and telomere biomarkers should not be translated into longevity outcomes.

Are injectable astragalus polysaccharides the same as capsules?

No. Injectable PG2 used in oncology trials has different composition, route and oversight. Its findings cannot be assigned to oral root products. [7]

Can astragalus be used with an autoimmune disease?

NCCIH advises people with autoimmune disease to avoid astragalus because it may worsen symptoms. [2]

Is astragalus safe during pregnancy or breastfeeding?

Reliable human safety evidence is lacking, and animal work raises fetal-toxicity concern. Health Canada and NCCIH advise professional review. [1], [2]

Glossary

Terms used in this guide.

Dried-root equivalent

The amount of starting dried root represented by an extract; it does not describe every constituent or make two extracts identical.

eGFR

Estimated glomerular filtration rate, a calculated measure used to assess kidney filtration over time.

UACR

Urine albumin-to-creatinine ratio, a measure of albumin in urine adjusted for urine concentration.

Surrogate outcome

A marker used in place of how a person feels, functions or survives; it may not translate into patient-important benefit.

Titration

Changing an amount in planned steps. The selected evidence does not establish a general astragalus titration.

Preclinical

Research outside trials in people, such as cell or animal experiments.

How this guide was researched

This draft used the May 2025 Health Canada monograph, NCCIH's May 2025 fact sheet, NCBI LiverTox, FDA guidance, primary oral trials and systematic reviews. Searches covered species and root identity, fatigue, diabetic kidney disease, type 2 diabetes, immune markers, autoimmune cautions, pregnancy, oral versus injectable preparations and liver safety.

Corrections to the legacy manuscript include removing generic extract and astragaloside-IV doses, removing “best form” and absorption claims, rejecting telomere biomarkers as longevity proof, separating injected PG2 from oral supplements, retaining the null UACR result, and replacing “immune boost” language with outcome-specific evidence. Evidence was refreshed October 9, 2026.

How this guide was made

The source ledger stores species, part, preparation, route, root equivalent, population, duration, outcomes, access and limitations. Primary studies support numeric rows; official sources frame safety and regulation. Draft status means scientific, French-parity, asset and rendered-page review remain separate gates.

Sources

Related guides